Aquaporin A/S Initiates Rights Issue for Enhanced Growth
Aquaporin A/S, a leading innovator in water technology committed to revolutionizing water filtration through biotechnology, has officially announced the initiation of a rights issue aimed at bolstering its financial standing. This significant move allows existing shareholders to acquire new shares in the company, aligning with its objective to enhance operational capacity and support future growth strategies.
Details of the Rights Issue
The Board of Directors of Aquaporin has authorized a rights issue to existing shareholders for the subscription of up to 77,536,770 new shares at a nominal value of DKK 1 each. The subscription price has been set at DKK 1 per new share, with a maximum gross proceeds expectation of around DKK 78 million should all shares be subscribed for. This capital will be essential for the company to maintain momentum and focus on its mission in the competitive water technology sector.
CEO's Perspective on the Initiative
Ulrik Lund Jakobsen, Chief Executive Officer of Aquaporin, expressed optimism about the rights issue, stating, "We are appreciative of the significant support from our shareholders, affirming our strategic direction. The raised capital will ensure we have sufficient resources to navigate the upcoming year effectively and continue executing our growth strategy driven by innovation. Our focus will remain on growing profitability through advanced water purification and separation technologies, with particular attention on Industrial Reverse Osmosis and Forward Osmosis mechanisms."
The Rationale Behind the Offering
The decision to launch this rights issue is driven by Aquaoprin's current financial positioning. The company anticipates that additional capital will be crucial to cover short-term expenses and strategic initiatives leading to profitability by mid-term. The proceeds from this offering will facilitate a strong commercial development path, enabling Aquaporin to explore various funding options until achieving sustainable profitability.
Subscription Details and Shareholder Benefits
For existing shareholders registered with Euronext Securities by the deadline of January 6, 2026, each will receive ten pre-emptive rights per share held, and three rights will be necessary to subscribe for one new share. This ratio provides an equitable opportunity for current shareholders to maintain their proportionate ownership in the company. It is noteworthy that any shareholder choosing not to participate in this offering may experience dilution of their shares by up to 77% if all new shares become subscribed.
A thorough assessment of the financial landscape has led the company to conclude that this rights issue aligns with its immediate funding requirements, positioning Aquaporin to navigate through fiscal year challenges, particularly as the second half of the year approaches.
Post-Issue Use of Proceeds
Once successfully funded, the gross proceeds will significantly support Aquaporin's operations, particularly financing the ongoing costs related to innovation in their Aquaporin Inside technology. This proprietary technology, rooted in Nobel Prize-winning research, is pivotal to the company's strategy for future projects targeting water filtration across varied industries. These funds will be instrumental in advancing to the commercialization phase of the second generation of the technology, known as Aquaporin Inside®.
Implications for Future Shareholders
For potential investors, the rights issue offers a timely entry point into Aquaporin as it seeks to enhance its market position. Moreover, the issuance of new shares emphasizes the company’s commitment to not only maintaining liquidity but also enhancing its technological advancements. The anticipated commercial use of the next-gen technology aims to address global water shortages, exploiting natural filtration methods that promise a reduction in operational costs for various sectors which rely on water usage.
Conclusion and Expectations
Aquaporin's rights issue signifies an essential phase in the company's growth trajectory, poised to unravel new possibilities in the water purification sector. With a focus on sustainability and innovation, the company aims to uphold its commitment to redefining water accessibility and efficiency globally. As the process unfolds, shareholders and prospective investors can anticipate a comprehensive information document detailing the offering's specifications, advantages, and conditions for participation. This strategic maneuver underscores Aquaporin's dedication to improving its operational framework while addressing essential water resource challenges globally.
Frequently Asked Questions
What is the purpose of Aquaporin's rights issue?
The rights issue aims to raise capital to support the company's growth strategy, operational expenses, and advancements in its Aquaporin Inside technology.
When will the subscription period for new shares commence?
The subscription period will start on January 7, 2026, and will close on January 20, 2026.
How many new shares can existing shareholders subscribe for?
Existing shareholders will receive ten pre-emptive rights for each share held, with three rights required to subscribe for one new share.
What will the proceeds from the rights issue be used for?
The proceeds are expected to fund operations and support the commercialization of the second-generation Aquaporin Inside technology.
What is the maximum potential dilution for shareholders who do not participate?
Shareholders who do not exercise their rights may face dilution of up to 77% if all new shares are subscribed for.
